WO1992000725A1 - Liquid oral pharmaceutical compositions having anti-inflammatory activity - Google Patents
Liquid oral pharmaceutical compositions having anti-inflammatory activity Download PDFInfo
- Publication number
- WO1992000725A1 WO1992000725A1 PCT/EP1991/001245 EP9101245W WO9200725A1 WO 1992000725 A1 WO1992000725 A1 WO 1992000725A1 EP 9101245 W EP9101245 W EP 9101245W WO 9200725 A1 WO9200725 A1 WO 9200725A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions according
- active ingredient
- ketoprofen
- cyclodextrins
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Definitions
- the present invention relates to liquid pharmaceu ⁇ tical compositions for the oral topical treatment, containing non steroidal anti-inflammatory drugs as the active ingredients.
- Therapeutical treatment of inflammations of the oral cavity such as aspecific odontostomatologic af ⁇ fections, gingivitis, glossitis, stomatitis and the like, is particularly complex and, until the specific pathogenic agent has precisely been determined, treat- ment can be restricted to the use of disinfectants of the general type.
- Said drugs besides showing negative characteri ⁇ stics (remarkable side-effects) can cause severe and diffused allergy phenomena, so as to compel to immedia- tely interrupt treatment and to take suitable restora ⁇ tion measures.
- compositions comprising non steroidal anti-inflammatory drugs (FANS) in form of solutions intended for the oral topical tre ⁇ atment (collutories) , allow to obtain very good thera ⁇ Promotionical results without causing sensitization pheno ⁇ mena.
- FANS non steroidal anti-inflammatory drugs
- the compositions of the invention are characteri ⁇ zed by the presence of a specific excipient, dimethyl isosorbide, giving them advantageous antiseptic proper ⁇ ties together with an antiplaque action which is parti- cularly desired in this kind of preparations.
- Anti-in ⁇ flammatory properties of the active ingredients also turn out to be surprisingly enhanced through a synerge- tic interaction with dimethyl isosorbide.
- compositions of the present invention can con- tain the active ingredient in amounts ranging from 0.001 to 20% by weight, whereas dimethyl isosorbide can be present in amounts ranging from 1 to 40% by weight.
- compositions of the invention can also contain other excipients and/or coadjuvants, such as surfactants, flavouring and sweetening agents, in order to give the preparation suitable organoleptic characteristics.
- excipients and/or co ⁇ adjuvants conventionally used for the preparation of collutories are described in "Remington's Pharm. Scien- ces Handbook", Mack Pub. Co., NY.
- the compositions of the invention will preferably contain natural and/or synthetic sweetening agents such as saccharine, ammo ⁇ nium glycyrrhizinate, cycla ate or, more preferably, not cariogenic carbohydrates such as xylitol and sorbi- tol.
- non steroidal anti- inflammatory drugs such as ketoprofen, ibuprofen, ibu- profen lysine salt, naproxen, suprofen, diclofenac, al- clofenac, indomethacin, acemethacin, benzidamine, flur- biprofen, piroxicam and the like, can be used as active ingredients, either in the free form or salified, in order to improve the solubility thereof.
- the active ingredients are present in combination with cyclodextrins or derivatives thereof, for example in form of physical admixtures, inclusion products or co- precipitates.
- Cyclodextrins or derivatives thereof such as hydroxypropyl beta-cyclodextrins, involve fa ⁇ vourable pharmacokinetic effects and, moreover, are useful to increase solubility and stability, or to im- prove the organoleptic characteristics of the medica ⁇ ment.
- Cyclodextrin contents can range from 0.5 to 50% by weight of the finished composition, but equimolecular ratios of active ingredient to cyclodextrin are prefe- rably used.
- cyclodex ⁇ trins (o , ⁇ , -) and the already cited hydroxypropyl ⁇ - cyclodextri ⁇ , dimethylcyclodextrins or other derivati ⁇ ves, possibly in a mixture thereof can also be used.
- polymers having an adhesive power towards ucosae are used as excipients.
- examples of said polymers are provided by carboxyvinyl polymers, ethyle e oxide - propylene oxide copolymers, cellulose derivatives such as carboxymethyl cellulose, calcium carboxymethyl cellulose, hydroxy- propylethyl cellulose, hydroxyethyl cellulose, hydroxy ⁇ propyl cellulose, carrageenan, dextrins, natural or synthetic gums and the like.
- Said excipients, which can be def ned bioadhesive polymers can be present in per ⁇ centages ranging from 0.5 to 30%, preferably from 1 to 5%.
- excipients allows to obtain sli ⁇ ghtly viscous solutions having adhesiveness towards mu- cosae, so as to achieve a better persistence of the preparation in contact with the area to be treated, thus obtaining a more effective and lasting action.
- compositions can also contain no dimethyl isosor- bide : said compositions also fall within the scope of the present invention.
- Each 15 ml ampoule contains: Active ingredient: ketoprofen Excipients:
- Ketoprofen is dissolved in an ethanol solution containing dimethyl isosorbide and Tween 60, the solu ⁇ tion is heated to 35 C C under stirring, to obtain a clear solution which is added with the other components. After filtration, a clear homogeneous solution (collutory) is obtained.
- Ketoprofen is added to a ⁇ -cyclodextrin aqueous solution (about 50 ml), which is heated to 30-40 e C for 30 hours. A solution is obtained which is added with dimethyl isosorbide and the other components, then fil ⁇ tered.
- EXAMPLE 4 Collutory containing ketoprofen, dimethyl isosorbide and bioadhesive polymers (in form of solution) 100 ml of collutory contain (% composition): Active ingredient: ketoprofen 0.05 Excipients:
- Each 15 ml ampoule contains : Active ingredient: Benzidamine 2 to 20 mg ExciDients: Tween 60 5 mg alpine herb flavor 52,503 T 15 mg dimethyl isosorbide 1500 mg
- Collutory containing piroxicam (in form of solution) 100 ml of collutory contain (% composition) : Active ingredient:
- Each 15 ml ampoule contains: Active ingredient: Piroxicam Excipients:
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1991911791 DE491897T1 (en) | 1990-07-13 | 1991-07-04 | LIQUID ANTI-FLAMMABLE MEDICINAL PRODUCTS. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT02094490A IT1243342B (en) | 1990-07-13 | 1990-07-13 | ORAL PHARMACEUTICAL COMPOSITIONS FOR LIQUID ANTI-INFLAMMATORY ACTIVITIES |
IT20944A/90 | 1990-07-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992000725A1 true WO1992000725A1 (en) | 1992-01-23 |
Family
ID=11174427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1991/001245 WO1992000725A1 (en) | 1990-07-13 | 1991-07-04 | Liquid oral pharmaceutical compositions having anti-inflammatory activity |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0491897A1 (en) |
AU (1) | AU8093591A (en) |
CA (1) | CA2066731A1 (en) |
ES (1) | ES2034926T1 (en) |
GR (1) | GR930300021T1 (en) |
IT (1) | IT1243342B (en) |
WO (1) | WO1992000725A1 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993025190A1 (en) * | 1992-06-10 | 1993-12-23 | Eastman Kodak Company | Surface modified nsaid nanoparticles |
EP0627915A1 (en) * | 1992-12-04 | 1994-12-14 | Mayor Pharmaceuticals Laboratories,Inc. | Sprayable analgesic composition and method of use |
WO1994028936A1 (en) * | 1993-06-08 | 1994-12-22 | Ciba-Geigy Ag | Process for the preparation of an oral solid dosage form containing diclofenac |
WO1995007104A1 (en) * | 1993-09-11 | 1995-03-16 | Smithkline Beecham Plc | Inclusion complexes of beta-cyclodextrin with flurbiprofen, ketoprofen and naproxen |
WO1995023591A1 (en) * | 1994-03-03 | 1995-09-08 | The Procter & Gamble Company | Oral vehicle compositions |
US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
WO1997003655A1 (en) * | 1995-07-20 | 1997-02-06 | Pharmacia & Upjohn Company | Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules |
US5626837A (en) * | 1993-08-12 | 1997-05-06 | Lion Corporation | Oral composition |
WO1997018802A1 (en) * | 1995-11-22 | 1997-05-29 | The Boots Company Plc | Pharmaceutical compositions comprising flurbiprofen |
US5674854A (en) * | 1993-10-08 | 1997-10-07 | Farmarc Nederland Bv | Inclusion complex of beta-cyclodextrin and diclofenac, its preparation and use |
US5679660A (en) * | 1993-12-02 | 1997-10-21 | Farmarc Nederland Bv | Pharmaceutical composition comprising diclofenac and cyclodextrin |
DE19651055A1 (en) * | 1996-12-09 | 1998-06-10 | Beiersdorf Ag | Stabilised light-protection combination, e.g. for cosmetic use |
WO1998052539A1 (en) * | 1997-05-22 | 1998-11-26 | The Boots Company Plc | Process for making flurbiprofen lozenges |
US6071964A (en) * | 1996-03-27 | 2000-06-06 | Hexal Ag | Diclofenac/gamma-cyclodextrin inclusion compounds |
ES2171110A1 (en) * | 2000-03-03 | 2002-08-16 | Aplicaciones Farmacodinamicas | Pharmaceutical composition based on ibuprofen and a procedure for the preparation thereof |
WO2003094905A1 (en) * | 2002-05-10 | 2003-11-20 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders |
WO2005074885A1 (en) * | 2004-02-03 | 2005-08-18 | Philippe Perovitch | Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method |
GB2416123B (en) * | 2003-04-07 | 2007-06-06 | Jurox Pty Ltd | Stable carprofen composition |
ES2347754A1 (en) * | 2009-04-27 | 2010-11-03 | Laboratorios De Aplicaciones Farmacodinamicas, S.A | Oral suspension of ibuprophene lisinate (Machine-translation by Google Translate, not legally binding) |
GB2486567A (en) * | 2010-12-15 | 2012-06-20 | Reckitt Benckiser Healthcare Int Ltd | Solutions of an NSAID and one or more cyclodextrins |
JP2012525359A (en) * | 2009-04-27 | 2012-10-22 | ラボラトリオ デ アプリカシオネス ファルマコディナミカス,エセ.アー. | Suspension for oral administration of ibuprofen ricinate |
US8580954B2 (en) | 2006-03-28 | 2013-11-12 | Hospira, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
WO2019105957A1 (en) * | 2017-11-30 | 2019-06-06 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Stable liquid composition of ketoprofen, salts and enantiomers thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0215423A2 (en) * | 1985-09-12 | 1987-03-25 | Dolorgiet GmbH & Co. KG | Transdermally resorbable aqueous compositions of arylpropionic-acid derivatives and process for their preparation |
EP0284588A1 (en) * | 1987-03-13 | 1988-09-28 | "PHARLYSE", Société Anonyme | Pharmaceutical preparation containing indomethacin |
WO1989004179A1 (en) * | 1987-11-03 | 1989-05-18 | Also Laboratori S.A.S. | Pharmaceutical formulations for transdermal administration |
-
1990
- 1990-07-13 IT IT02094490A patent/IT1243342B/en active IP Right Grant
-
1991
- 1991-07-04 EP EP91911791A patent/EP0491897A1/en not_active Withdrawn
- 1991-07-04 ES ES199191911791T patent/ES2034926T1/en active Pending
- 1991-07-04 WO PCT/EP1991/001245 patent/WO1992000725A1/en not_active Application Discontinuation
- 1991-07-04 AU AU80935/91A patent/AU8093591A/en not_active Abandoned
- 1991-07-04 CA CA002066731A patent/CA2066731A1/en not_active Abandoned
-
1993
- 1993-04-28 GR GR930300021T patent/GR930300021T1/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0215423A2 (en) * | 1985-09-12 | 1987-03-25 | Dolorgiet GmbH & Co. KG | Transdermally resorbable aqueous compositions of arylpropionic-acid derivatives and process for their preparation |
EP0284588A1 (en) * | 1987-03-13 | 1988-09-28 | "PHARLYSE", Société Anonyme | Pharmaceutical preparation containing indomethacin |
WO1989004179A1 (en) * | 1987-11-03 | 1989-05-18 | Also Laboratori S.A.S. | Pharmaceutical formulations for transdermal administration |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
WO1993025190A1 (en) * | 1992-06-10 | 1993-12-23 | Eastman Kodak Company | Surface modified nsaid nanoparticles |
EP0627915A1 (en) * | 1992-12-04 | 1994-12-14 | Mayor Pharmaceuticals Laboratories,Inc. | Sprayable analgesic composition and method of use |
EP0627915A4 (en) * | 1992-12-04 | 1996-02-07 | Mayor Pharma Lab Inc | Sprayable analgesic composition and method of use. |
WO1994028936A1 (en) * | 1993-06-08 | 1994-12-22 | Ciba-Geigy Ag | Process for the preparation of an oral solid dosage form containing diclofenac |
US5702724A (en) * | 1993-06-08 | 1997-12-30 | Ciba-Geigy Corporation | Process for the preparation of an oral solid dosage form containing diclofenac |
US5626837A (en) * | 1993-08-12 | 1997-05-06 | Lion Corporation | Oral composition |
WO1995007104A1 (en) * | 1993-09-11 | 1995-03-16 | Smithkline Beecham Plc | Inclusion complexes of beta-cyclodextrin with flurbiprofen, ketoprofen and naproxen |
US5674854A (en) * | 1993-10-08 | 1997-10-07 | Farmarc Nederland Bv | Inclusion complex of beta-cyclodextrin and diclofenac, its preparation and use |
US5679660A (en) * | 1993-12-02 | 1997-10-21 | Farmarc Nederland Bv | Pharmaceutical composition comprising diclofenac and cyclodextrin |
WO1995023591A1 (en) * | 1994-03-03 | 1995-09-08 | The Procter & Gamble Company | Oral vehicle compositions |
AU702889B2 (en) * | 1994-03-03 | 1999-03-11 | Procter & Gamble Company, The | Oral vehicle compositions |
WO1997003655A1 (en) * | 1995-07-20 | 1997-02-06 | Pharmacia & Upjohn Company | Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules |
WO1997018802A1 (en) * | 1995-11-22 | 1997-05-29 | The Boots Company Plc | Pharmaceutical compositions comprising flurbiprofen |
US5889057A (en) * | 1995-11-22 | 1999-03-30 | The Boots Company Plc | Flurbiprofen lozenge for the treatment of sore throat |
AU707749B2 (en) * | 1995-11-22 | 1999-07-22 | Reckitt Benckiser Healthcare (Uk) Limited | Medical Treatment |
US6166083A (en) * | 1995-11-22 | 2000-12-26 | The Boots Company, Plc | Suckable flurbiprofen lozenges for treatment of sore throat |
US6071964A (en) * | 1996-03-27 | 2000-06-06 | Hexal Ag | Diclofenac/gamma-cyclodextrin inclusion compounds |
DE19651055A1 (en) * | 1996-12-09 | 1998-06-10 | Beiersdorf Ag | Stabilised light-protection combination, e.g. for cosmetic use |
DE19651055B4 (en) * | 1996-12-09 | 2006-03-16 | Beiersdorf Ag | Cosmetic and dermatological sunscreen formulations containing triazine derivatives and dimethyl isosorbide and their use |
US6194003B1 (en) | 1997-05-22 | 2001-02-27 | The Boots Company Plc | Process for making flurbiprofen lozenges |
WO1998052539A1 (en) * | 1997-05-22 | 1998-11-26 | The Boots Company Plc | Process for making flurbiprofen lozenges |
ES2171110A1 (en) * | 2000-03-03 | 2002-08-16 | Aplicaciones Farmacodinamicas | Pharmaceutical composition based on ibuprofen and a procedure for the preparation thereof |
WO2003094905A1 (en) * | 2002-05-10 | 2003-11-20 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders |
CN1303992C (en) * | 2002-05-10 | 2007-03-14 | 方济各安吉利克化学联合股份有限公司 | Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders |
GB2416123B (en) * | 2003-04-07 | 2007-06-06 | Jurox Pty Ltd | Stable carprofen composition |
US8846083B2 (en) | 2004-02-03 | 2014-09-30 | Philippe Perovitch | Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method |
EP1711162B1 (en) | 2004-02-03 | 2017-11-01 | Philippe Perovitch | Composition for use in the local treatment of oropharyngeal conditions comprising ibuprofen or ketoprofen |
WO2005074885A1 (en) * | 2004-02-03 | 2005-08-18 | Philippe Perovitch | Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method |
US8580954B2 (en) | 2006-03-28 | 2013-11-12 | Hospira, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
US8946292B2 (en) | 2006-03-28 | 2015-02-03 | Javelin Pharmaceuticals, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
JP2012525359A (en) * | 2009-04-27 | 2012-10-22 | ラボラトリオ デ アプリカシオネス ファルマコディナミカス,エセ.アー. | Suspension for oral administration of ibuprofen ricinate |
ES2347754A1 (en) * | 2009-04-27 | 2010-11-03 | Laboratorios De Aplicaciones Farmacodinamicas, S.A | Oral suspension of ibuprophene lisinate (Machine-translation by Google Translate, not legally binding) |
GB2486567B (en) * | 2010-12-15 | 2014-09-10 | Reckitt Benckiser Healthcare Int Ltd | Pharmaceutical formulation |
WO2012080718A1 (en) * | 2010-12-15 | 2012-06-21 | Reckitt Benckiser Healthcare International Limited | Novel pharmaceutical formulation comprising nsaid and cyclodextrin |
US9138482B2 (en) | 2010-12-15 | 2015-09-22 | Reckitt Benckiser Healthcare International Limited | Pharmaceutical formulation comprising NSAID and cyclodextrin |
RU2607592C2 (en) * | 2010-12-15 | 2017-01-10 | Рекитт Бенкизер Хелскэа Интернэшнл Лимитед | New pharmaceutical composition containing nsaid and cyclodextrin |
GB2486567A (en) * | 2010-12-15 | 2012-06-20 | Reckitt Benckiser Healthcare Int Ltd | Solutions of an NSAID and one or more cyclodextrins |
US10363316B2 (en) | 2010-12-15 | 2019-07-30 | Reckitt Benckiser Healthcare (Uk) Limited | Pharmaceutical formulation comprising NSAID and cyclodextrin |
WO2019105957A1 (en) * | 2017-11-30 | 2019-06-06 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Stable liquid composition of ketoprofen, salts and enantiomers thereof |
Also Published As
Publication number | Publication date |
---|---|
GR930300021T1 (en) | 1993-04-28 |
ES2034926T1 (en) | 1993-04-16 |
IT9020944A0 (en) | 1990-07-13 |
IT1243342B (en) | 1994-06-10 |
CA2066731A1 (en) | 1992-01-14 |
AU8093591A (en) | 1992-02-04 |
EP0491897A1 (en) | 1992-07-01 |
IT9020944A1 (en) | 1992-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1992000725A1 (en) | Liquid oral pharmaceutical compositions having anti-inflammatory activity | |
EP0441307B1 (en) | Syrup composition | |
KR100439090B1 (en) | Taste-masking liquid | |
CA1234050A (en) | Injectable solution for the treatment of inflammations | |
EP0444492B1 (en) | Topically administered compositions based on high molecular weight hyaluronic acid for treating inflammations of the oral cavity, and for oral cavity hygiene and cosmetic treatment | |
JPH05504783A (en) | Highly water-soluble cyclodextrin derivative composition and its uses | |
PT1609481E (en) | Injectable pharmaceutical compositions comprising sodium diclofenac, beta-cyclodextrin and a polysorbate | |
PT1998762E (en) | Solid dosage form containing a taste masked active agent | |
KR20030069979A (en) | Pharmaceutical compositions for the treatment of mucositis, stomatitis and Behcet's syndrome | |
JP2002510652A5 (en) | ||
JPH0257049B2 (en) | ||
AU2002306329B2 (en) | Aqueous cilostazol preparation for injection | |
KR20040084891A (en) | Taste masking spill-resistant formulation | |
EP1974751A1 (en) | Formulations for non-steroidal anti-inflammatory drugs | |
EP0633787B1 (en) | Use of ibuprofen-beta-cyclodextrin complex for oral consumption | |
AU2003232480B2 (en) | Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders | |
WO2005065674A1 (en) | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid | |
JPH0616547A (en) | Antiphlogistic ophthalmic solution | |
JPH035438A (en) | Flurbiprofen clathrate compound and anti-inflammatory and analgesic agent using the same clathrate compound | |
EP0867181A1 (en) | Nasal melatonin composition | |
CA2259270C (en) | Pharmaceutical preparation containing nimesulide for oral administration | |
JPS6393718A (en) | Injection | |
KR20040079012A (en) | Acetylcysteine oral dosage forms | |
EP1242062B1 (en) | Anhydrous gel comprising nsaid for topical administration to the oral cavity | |
KR100567131B1 (en) | Taste masking of oral ibuprofen and arginine solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MC MG MN MW NO PL RO SD SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991911791 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2066731 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1991911791 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1991911791 Country of ref document: EP |